Haplotype variations in glutathione transferase zeta 1 influence the kinetics and dynamics of chronic dichloroacetate in children

Journal of Clinical Pharmacology

Volumn 55, Issue 1, 2015, Pages 50-55

  Shroads, A L ^a   Coats, B S ^a   McDonough, C W ^a   Langaee, T ^a,b   Stacpoole, P W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

congenital lactic acidosis; dichloroacetate; glutathione transferase zeta 1; maleylacetoacetate isomerase; mitochondrial disease; pharmacogenetics; pharmacokinetics; tyrosine

Indexed keywords

ACETONE; DICHLOROACETIC ACID; DICHLOROACETIC ACID C 13; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE ZETA 1; ISOMERASE; MALEYLACETOACETATE ISOMERASE; MALEYLACETONE; PLACEBO; TRACER; UNCLASSIFIED DRUG; AMINOLEVULINIC ACID; GSTZ1 PROTEIN, HUMAN; MALEIC ACID DERIVATIVE; TYROSINE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; ELIMINATION HALF-LIFE; ENZYME SYNTHESIS; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TYROSINEMIA; ANALOGS AND DERIVATIVES; BLOOD; GENETIC DISEASES, INBORN; GENETICS; INFANT; KINETICS; METABOLISM; MITOCHONDRIAL DISEASES; URINE; YOUNG ADULT;

ACETONE; ADOLESCENT; ADULT; AMINOLEVULINIC ACID; CHILD; CHILD, PRESCHOOL; DICHLOROACETIC ACID; DOUBLE-BLIND METHOD; FEMALE; GENETIC DISEASES, INBORN; GLUTATHIONE TRANSFERASE; HAPLOTYPES; HUMANS; INFANT; KINETICS; MALE; MALEATES; MITOCHONDRIAL DISEASES; POLYMORPHISM, SINGLE NUCLEOTIDE; TYROSINE; YOUNG ADULT;

EID: 84919710714     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.371     Document Type: Article

References (19)

1. Patel MS, Korotchkina LG,. Regulation of mammalian pyruvate dehydrogenase complex by phosphorylation: complexity of multiple phosphorylation sites and kinases. Exp Mol Med. 2001; 33 (4): 191-197.
2. Bowker-Kinley MM, Davis WI, Wu P, Harris RA, Popov KM,. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J. 1998; 329: 191-196.
3. Kaplon J, Zheng L, Meissl K, et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature. 2013; 498 (7452): 109-112.
4. Stacpoole PW,. The dichloroacetate dilemma: environmental hazard versus therapeutic goldmine-both or neither? Environ Health Perspect. 2011; 119 (2): 155-158.
5. Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology. 2006; 66 (3): 324-330.
6. Abdelmalak M, Lew A, Ramezani R, et al. Long-term safety of dichloroacetate in congenital lactic acidosis. Mol Genet Metab. 2013; 109 (2): 139-143.
7. Stacpoole PW, Kurtz TL, Han Z, Langaee TY, Role of dichloroacetate in the treatment of genetic mitochondrial diseases. In Mitochondrial Medicine and Mitochondrion-Based Therapeutics. Advanced Drug Delivery Reviews. Elsevier 2008; 60: 1478-87.
8. Shroads AL, Langaee T, Coats BS, et al. Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate. J Clin Pharmacol. 2012; 52: 837-849.
9. Tanguay RM, Lambert M, Grompe M, Mitchell GA., Hypertyrosinemia. In: Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2004: 1777-1805.
10. Stacpoole PW, Kerr DS, Barnes C, et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics. 2006; 117: 1519-1531.
11. Stacpoole PW, Gilbert LR, Neiberger RE, et al. Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate. Pediatrics. 2008; 121: e1223-e1228.
12. Shroads AL, Henderson GN, Cheung J, James MO, Stacpoole PW,. Unified gas chromatographic-mass spectrometric method for quantitating tyrosine metabolites in urine and plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 808: 153-61.
13. Felitsyn NM, Henderson GN, James MO, Stacpoole PW,. Liquid chromatography-tandem mass spectrometry method for the simultaneous determination of delta-ALA, tyrosine and creatinine in biological fluids. Clin Chim Acta. 2004; 350: 219-230.
14. Stephens M, Smith NJ, Donnelly P,. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001; 68: 978-989.
15. Anderson WB, Board PG, Gargano B, Anders MW,. Inactivation of glutathione transferase zeta by dichloroacetic acid and other fluorine-lacking alpha-haloalkanoic acids. Chem Res Toxicol. 1999; 12 (12): 1144-1149.
16. James MO, Cornett R, Yan Z, Henderson GN, Stacpoole PW,. Glutathione-dependent conversion to glyoxylate, a major pathway of dichloroacetate biotransformation in hepatic cytosol from humans and rats, is reduced in dichloroacetate-treated rats. Drug Metab Dispos. 1997; 25 (11): 1223-1227.
17. Ammini CV, Fernandez-Canon J, Shroads AL, et al. Pharmacologic or genetic ablation of maleylacetoacetate isomerase increases levels of toxic tyrosine catabolites in rodents. Biochem Pharmacol. 2003; 66 (10): 2029-2038.
18. Guo X, Dixit V, Liu H, et al. Inhibition and recovery of rat hepatic glutathione S-transferase zeta and alteration of tyrosine metabolism following dichloroacetate exposure and withdrawal. Drug Metab Dispos 2006; 34 (1): 36-42.
19. E.M. Dunbar, B.S. Coats, A.L. Shroads, et al. Phase 1 trial of fichloroacetate (DCA) in adults with recurrent malignant brain tumors Invest New Drugs. 2014; DOI: 10.1007/s10637-013-0047-4.